ReviewMaterials (Basel, Switzerland)2019
Dendrimers as Pharmaceutical Excipients: Synthesis, Properties, Toxicity and Biomedical Applications.
Review in Materials (Basel, Switzerland), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 88 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
88 citing papers in PubMed, 1 synthesis or guideline pooled it.
- A systemic review on development of mesoporous nanoparticles as a vehicle for transdermal drug delivery.Nanotheranostics · 2023Pooled it
- Breaking Biological Barriers: Engineering Nanocarriers for Efficient Drug and Gene Delivery through Nano-Bio Interfaces and Biophysical Design.Applied physics reviews · 2026Article
- Toxicity of the Antiretrovirals Lamivudine, Dolutegravir, and Tenofovir on the MicroalgaACS omega · 2026Article
- Neuroprotective role of cyanidin in Alzheimer's and Parkinson's disease: current insights and the road ahead.Inflammopharmacology · 2026Review
- The Second Hyper-Zagreb Index and Coindex of Chemical Nano-structures in Drugs.Pharmaceutical nanotechnology · 2026Article
- Nanotechnological Advances in Ocular Therapeutics: A Narrative Review of Drug Delivery Platforms, Clinical Applications, and Translational Challenges.Nanotechnology, science and applications · 2026Review
- Nanoparticle-based approaches for vascular inflammation in managing hypertension: advancing molecular mechanisms and treatment strategies.Drug delivery and translational research · 2026Review
- PAMAM dendrimers as efficient drug nanocarriers of natural compounds in breast cancer therapeutics.Frontiers in oncology · 2026Review
- Overview of dendrimers as promising drug delivery systems with insight into anticancer and anti-microbial applications.International journal of pharmaceutics: X · 2025Review
- Innovative approaches in breast cancer therapy: repurposing nanocarriers for enhanced outcomes.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Radiolabeled Nanogels: From Multimodality Imaging to Combination Therapy of Cancer.Small science · 2025Review
- Emerging Nanotechnology Strategies for Obesity Therapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- Recent advancements in polymer science for retinal diseases: New frontiers in drug delivery systems.APL bioengineering · 2025Article
- Molecular Mechanisms of Action of Dendrimers with Antibacterial Activities on Model Lipid Membranes.Polymers · 2025Article
- Evaluation of Drug-Polymer and Drug-Drug Interaction in Cellulosic Multi-Drug Delivery Matrices.Methods and protocols · 2025Article
- Nanotherapeutics for Meningitis: Enhancing Drug Delivery Across the Blood-Brain Barrier.Biomimetics (Basel, Switzerland) · 2025Review
- Advancing Amyloid Aggregation Research: A Focus on Innovative Therapies, Molecular Modeling and Nano-Delivery Systems in Alzheimer's Disease.Current drug targets · 2025Review
- Reproductive Toxicity of Nanoparticles: A Comprehensive Review.Current medicinal chemistry · 2025Review
- Nano-Drug Delivery Systems Targeting MMPs: A Promising Treatment for Gliomas.International journal of nanomedicine · 2025Review
- Recent Advancements in Nanopharmaceuticals for Novel Drug Delivery Systems.Pharmaceutical nanotechnology · 2025Review
28 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
The European Medicines Agency (EMA) and the Current Good Manufacturing Practices (cGMP) in the United States of America, define excipient as the constituents of the pharmaceutical form other than the active ingredient, i.e., any component that is intended to furnish pharmacological activity. Although dendrimers do not have a pharmacopoeia monograph and, therefore, cannot be recognized as a pharmaceutical excipient, these nanostructures have received enormous attention from researchers. Due to their unique properties, like the nanoscale uniform size, a high degree of branching, polyvalency, aqueous solubility, internal cavities, and biocompatibility, dendrimers are ideal as active excipients, enhancing the solubility of poorly water-soluble drugs. The fact that the dendrimer's properties are controllable during their synthesis render them promising agents for drug-delivery applications in several pharmaceutical formulations. Additionally, dendrimers can be used for reducing the drug toxicity and for the enhancement of the drug efficacy. This review aims to discuss the properties that turn dendrimers into pharmaceutical excipients and their potential applications in the pharmaceutical and biomedical fields.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.